This survey study described the burden of high-dose U-100 basal-bolus insulin therapy (total daily dose >200 units) and associated dosing behaviors in patients with type 2 diabetes (T2D). Patients reported being compliant with prescribed daily basal-bolus insulin doses. Approximately half of the patients reported missing/skipping doses and underdosing for a variety of reasons. Study results provide a better understanding of patient adherence and the burden associated with high-dose U-100 basal-bolus regimen and can help address the treatment concerns, motivations, barriers, and satisfaction of patients on high-dose insulin.
